INSMED INC Amortization of Debt Discount (Premium)
INSMED INC (INSM) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2024-02-22
- INSMED INC amortization of debt discount (premium) for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC amortization of debt discount (premium) for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- INSMED INC amortization of debt discount (premium) for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- INSMED INC amortization of debt discount (premium) for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC amortization of debt discount (premium) for fiscal 2023 was $0.00.
- INSMED INC amortization of debt discount (premium) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- INSMED INC amortization of debt discount (premium) for fiscal 2021 was $29.15M, a 53.57% increase from fiscal 2020.
- INSMED INC amortization of debt discount (premium) for fiscal 2020 was $18.98M, a 5.54% increase from fiscal 2019.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 10-Q · filed 2022-10-27 | $0.00 derived: sum of 2 quarters · filed 2022-10-27 | $0.00 10-Q · filed 2022-10-27 | $8.44M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $8.44M derived: sum of 3 quarters · filed 2024-02-22 | $16.76M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $8.44M derived: sum of 2 quarters · filed 2024-02-22 | $16.76M derived: sum of 3 quarters · filed 2024-02-22 | $24.24M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $8.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $16.76M derived: sum of 2 quarters · filed 2024-02-22 | $24.24M derived: sum of 3 quarters · filed 2024-02-22 | $29.15M 10-K · filed 2024-02-22 |
| 2021-09-30 | $8.32M 10-Q · filed 2022-10-27 | $15.80M derived: sum of 2 quarters · filed 2022-10-27 | $20.71M 10-Q · filed 2022-10-27 | $25.55M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $7.48M 10-Q · filed 2022-08-04 | $12.39M 10-Q · filed 2022-08-04 | $17.23M derived: sum of 3 quarters · filed 2023-02-23 | $22.01M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $4.91M 10-Q · filed 2022-05-05 | $9.75M derived: sum of 2 quarters · filed 2023-02-23 | $14.53M derived: sum of 3 quarters · filed 2023-02-23 | $19.24M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $9.62M derived: sum of 2 quarters · filed 2023-02-23 | $14.33M derived: sum of 3 quarters · filed 2023-02-23 | $18.98M 10-K · filed 2023-02-23 |
| 2020-09-30 | $4.78M 10-Q · filed 2021-10-28 | $9.49M derived: sum of 2 quarters · filed 2021-10-28 | $14.14M 10-Q · filed 2021-10-28 | $18.73M derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-06-30 | $4.71M 10-Q · filed 2021-08-05 | $9.36M 10-Q · filed 2021-08-05 | $13.95M derived: sum of 3 quarters · filed 2022-02-17 | $18.48M derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-03-31 | $4.65M 10-Q · filed 2021-05-06 | $9.24M derived: sum of 2 quarters · filed 2022-02-17 | $13.76M derived: sum of 3 quarters · filed 2022-02-17 | $18.23M derived: sum of 4 quarters · filed 2022-02-17 |
| 2019-12-31 | $4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $9.11M derived: sum of 2 quarters · filed 2022-02-17 | $13.58M derived: sum of 3 quarters · filed 2022-02-17 | $17.98M 10-K · filed 2022-02-17 |
| 2019-09-30 | $4.53M 10-Q · filed 2020-10-29 | $8.99M derived: sum of 2 quarters · filed 2020-10-29 | $13.40M 10-Q · filed 2020-10-29 | $17.75M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $4.47M 10-Q · filed 2020-08-06 | $8.87M 10-Q · filed 2020-08-06 | $13.22M derived: sum of 3 quarters · filed 2021-02-25 | $17.51M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $4.41M 10-Q · filed 2020-04-30 | $8.75M derived: sum of 2 quarters · filed 2021-02-25 | $13.04M derived: sum of 3 quarters · filed 2021-02-25 | $17.27M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $8.64M derived: sum of 2 quarters · filed 2021-02-25 | $12.87M derived: sum of 3 quarters · filed 2021-02-25 | $15.89M 10-K · filed 2021-02-25 |
| 2018-09-30 | $4.29M 10-Q · filed 2019-10-30 | $8.52M derived: sum of 2 quarters · filed 2019-10-30 | $11.54M 10-Q · filed 2019-10-30 | $11.54M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $4.23M 10-Q · filed 2019-08-01 | $7.25M 10-Q · filed 2019-08-01 | $7.25M derived: sum of 3 quarters · filed 2020-02-25 | $7.25M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $3.02M 10-Q · filed 2019-05-07 | $3.02M derived: sum of 2 quarters · filed 2020-02-25 | $3.02M derived: sum of 3 quarters · filed 2020-02-25 | $3.02M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $0.00 10-K · filed 2020-02-25 |
| 2017-09-30 | $0.00 10-Q · filed 2018-10-30 | $0.00 derived: sum of 2 quarters · filed 2018-10-30 | $0.00 10-Q · filed 2018-10-30 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-02 | |||
| 2012-12-31 | $236.00K 10-K · filed 2013-03-18 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-03-18 | |||
| 2010-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |